Cu-67-SARbisPSMA

⁶⁷Cu-SARbisPSMA)) is a new PSMA targeting drug labeled with ⁶⁷Cu and developed by the Australian company Clarity Pharmaceuticals as therapeutic analogue of ⁶⁴Cu-SARbisPSMA. The first US Phase I/II clinical trial involving both ⁶⁴Cu/⁶⁷Cu-SARbisPSMA Phase I/II trial is expected to start inclusion before end of the year 2021

Target/Mechanism: PSMA

Leading Emitter: beta electrons (β^–)